53 results on '"Deng, Shuhui"'
Search Results
2. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
3. The impact of response kinetics for multiple myeloma in the era of novel agents
4. Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
5. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma
6. Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases
7. Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival
8. Secondary Monoclonal Gammopathy of Undetermined Significance Is Frequently Associated with High Response Rate and Superior Survival in Patients with Plasma Cell Dyscrasias
9. The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
10. t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome
11. P-362 ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity
12. P-191 Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents
13. OA-18 Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing
14. A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma
15. Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation
16. Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?
17. P-226: Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
18. P-089: Disordered metabolism mediates the immunosuppressive microenvironment in multiple myeloma
19. P-054: Neoplastic plasma cells in stem cell collection have no effect on the survival of multiple myeloma patients receiving autologous stem cell transplantation
20. P-044: Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma
21. Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)
22. P-174: Clinical study of bortezomib-based regimens of BCD, PAD and VDD for newly diagnosed multiple myeloma – an analysis of 400 cases in a single center of China
23. The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma
24. Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
25. Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients
26. Novel Insight into Multi-Hit Multiple Myeloma Based on “Two-Hit” Theory of Cancer Causation
27. Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level
28. Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies
29. Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment
30. Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients
31. Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China
32. Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance
33. Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma
34. Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma
35. Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma
36. 1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma
37. Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients
38. The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy
39. Clinical Characteristics, Survival Outcomes and prognosis in 82 Immunoglobulin D Multiple Myeloma Patients: A Retrospective Single-Center Study
40. Real-world Outcomes of Chinese patients with high-risk Multiple Myeloma
41. The prognostic impact of dynamic changing of cytogenetic abnormalities under the treatment options in multiple myeloma
42. YWHAE/14-3-3ε expression impacts the proteasome load contributing to proteasome inhibitor sensitivity in multiple myeloma
43. The bone marrow microenvironment of multiple myeloma promotes myeloma related anemia by suppressing the differentiation of hematopoietic stem cells
44. Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients
45. IgH translocations with undefined partners are associated with superior outcome in multiple myeloma patients
46. The prognostic value of 1q21 gain does not rely on the copy numbers, clone size and concurrence with t(4;14)
47. PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma
48. Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy
49. Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis
50. Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.